Journal
NEUROPHARMACOLOGY
Volume 52, Issue 2, Pages 395-404Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2006.08.010
Keywords
imidazoline binding site; monoamine oxidase; MAO; BU99006; 2BFI; autoradiography; I-2
Categories
Funding
- Wellcome Trust Funding Source: Medline
Ask authors/readers for more resources
BU99006 is an irreversible I2 ligand which selectively inactivates 12 binding sites, making it an ideal tool with which to study 1, site mechanism. We sought to determine the effects of BU99006 on 12 binding in relation to monoamine oxidase (MAO), and the time course of these effects. In vitro, rat brain membranes that were pre-treated with 10 mu M BU99006 showed no change in MAO activity, despite suffering a significant reduction in [H-3]2BFI binding (52.5 +/- 19.6 to 8.5 +/- 3.8 fmol mg(-1), 84%). Furthermore, reversible I-2 ligands 2BFI and BU224 were able to inhibit MAO, whether treated with BU99006 or not. In vivo, a 5 mg kg(-1) i.v. dose of BU99006 in rats rapidly reduced [H-3]2BFI binding with similar magnitude (85%, maximal reduction after 20 min), without effect on either MAO activity or the specific binding of selective MAOA and MAO-B radioligands. Moreover, following this irreversible treatment, recovery of central [H-3]2BFI binding occurred with a rapid half-life of 4.3 h in rat brain (2.0 h in mouse), which is not consistent with a site on MAO. These data indicate that the high affinity site which is occupied by [H-3]2BFI and irreversibly binds BU99006, is not the same as that which causes inhibition of MAO, and may point to the existence of another 12 binding site. (c) 2006 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available